Login to Your Account



Otsuka 'checks all the boxes' for Akebia in potential $1B+ vadadustat deal

By Marie Powers
News Editor

Tuesday, December 20, 2016

While most analysts and investors were focused on its discussions with potential European partners, Akebia Therapeutics Inc. turned to Asia, again, for a U.S. development and commercialization collaborator for its lead candidate, vadadustat.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription